Table 2.
Characteristics of hepatitis B vaccine responders and non-responders
| Characteristics | Results of testing for anti-HBs | P-value | |
|---|---|---|---|
| Negative | Positive | ||
| (n=113) | (n=189) | ||
| n (%) | n (%) | ||
| Age, mean years±SD | 36.5±6.9 | 35.8±8.8 | 0.418 |
| Female gender | 34(30.9) | 85(44.9) | 0.010 |
| History of intravenous drug use | 41(39.4) | 54(30.9) | 0.144 |
| Receipt of ART | 100(88.5) | 149(78.8) | 0.033 |
| WHO clinical stage 1 or 2 | 95(84.1) | 179(94.7) | <0.001 |
| Hepatitis B core antibody positive | 33(58.9) | 65(61.9) | 0.712 |
| Hepatitis C antibody positive | 52(46.0) | 68(36.0) | 0.084 |
| ALT ≥100 IU/mL | 7(6.4) | 24(13.0) | 0.081 |
| Nadir CD4 T cell count <100 cells/μL | 61(54.0) | 75(40.3) | 0.021 |
| CD4 T cell count prior to vaccination <200 cells/μL | 67(59.3) | 52(27.7) | <0.0001 |
| Plasma HIV RNA closest to first vaccine dose <48 copies/mL | 36(45.0) | 58(42.3) | 0.702 |